Press release - 04/03/2021 CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Novartis AG announced today that they have signed an initial agreement for the manufacturing of CureVac’s COVID-19 vaccine candidate, CVnCoV. Preparations for the start of production, technology transfers and test runs are already underway. https://www.gesundheitsindustrie-bw.de:443/en/article/press-release/curevac-and-novartis-sign-initial-agreement-manufacturing-covid-19-vaccine-candidate-cvncov
Press release - 01/02/2021 Targeting a rapid market breakthrough for new vaccine production method In a so-called inactivated or killed vaccine, the virus particles it contains are first rendered inactive by means of the toxic chemical formaldehyde. A better way of achieving this, however, is to irradiate the pathogens with low-energy electrons. Four Fraunhofer Institutes have now developed a new method of vaccine production based on this technique that is not only quicker but also guarantees a higher quality of product. https://www.gesundheitsindustrie-bw.de/en/article/press-release/targeting-rapid-market-breakthrough-new-vaccine-production-method
Press release - 11/01/2021 CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating the induction of robust antibody and T cell responses of its COVID-19 vaccine candidate, CVnCoV, in non-human primates. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevacs-covid-19-vaccine-candidate-cvncov-demonstrated-efficient-protection-non-human-primates-during-sars-cov-2-challenge-infe
Press release - 07/01/2021 CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV Bayer has signed a collaboration and services agreement with CureVac, a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid. Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate CVnCoV. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-bayer-join-forces-covid-19-vaccine-candidate-cvncov
Press release - 22/12/2020 Voluntary or compulsory? New evidence on motivation for anti-Covid-19 policies A study by the University of Konstanz shows that voluntary motivation to comply with anti-Covid-19 policies is relatively high in Germany, but can be undermined by enforcement - The consequence of this finding differs depending on the policy.https://www.gesundheitsindustrie-bw.de/en/article/press-release/voluntary-or-compulsory-new-evidence-motivation-anti-covid-19-policies
Press release - 01/12/2020 Novel vaccine trial to activate T-cell responses against SARS-CoV-2 A Phase I clinical trial using a self-developed vaccine against SARS-CoV-2 was initiated today at the University Hospital of Tübingen. In contrast to the currently evaluated vaccine candidates against COVID-19, the vaccine CoVAC1, developed by the Department of Immunology (Director Prof. Hans-Georg Rammensee) at the University of Tübingen, aims specifically at the induction of a T-cell-mediated immune response against SARS-COV-2.https://www.gesundheitsindustrie-bw.de/en/article/press-release/Novel-vaccine-trial-to-activate-T-cell-responses-against-SARS-CoV-2
Press release - 16/11/2020 European Commission Announces That Tomorrow It Will Authorize the Agreement with CureVac for the Supply of up to 405 Million Doses of mRNA-Based COVID-19 Vaccine Candidate, CVnCoV CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), reports the European Commission’s announcement that tomorrow it will authorize an Advanced Purchase Agreement for CureVac´s mRNA-based COVID-19 vaccine candidate, CVnCoV.https://www.gesundheitsindustrie-bw.de/en/article/press-release/european-commission-announces-tomorrow-it-will-authorize-agreement-curevac-supply-405-million-doses-mrna-based-covid-19-vaccine
Funding TRANSVAC: New Vaccines Faster Funding programme, Funded by: Horizon2020, Submission deadline: 15/04/2021 https://www.gesundheitsindustrie-bw.de:443/en/database/funding/transvac-new-vaccines-faster
Press release - 02/11/2020 CureVac Reports Positive Interim Phase 1 Data for its COVID-19 Vaccine Candidate, CVnCoV CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced positive interim data from its ongoing Phase 1 dose-escalation study evaluating the safety, reactogenicity and immunogenicity of CVnCoV, its investigational SARS-CoV-2 vaccine candidate. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-reports-positive-interim-phase-1-data-its-covid-19-vaccine-candidate-cvncov
Press release - 23/10/2020 CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced data from preclinical studies of its investigational SARS-CoV-2 vaccine candidate, CVnCoV, in mice and hamsters.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-reports-positive-preclinical-data-its-covid-19-vaccine-candidate-cvncov
Press release - 20/10/2020 EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses. RNA viruses cause diseases such as influenza, SARS and COVID-19. https://www.gesundheitsindustrie-bw.de/en/article/press-release/eib-backs-atriva-therapeutics-eur24-million-development-potential-covid-19-treatment
KyooBe Tech GmbH - 08/10/2020 Next generation vaccine production For decades, conventional inactivated vaccines have been produced by killing pathogens with toxic chemicals. However, this process often changes the surface structure of the pathogens to such an extent that the immune system is only able to induce a weak response. KyooBe Tech GmbH is offering a method that uses low-energy electrons to inactivate pathogens. Vaccines produced this way are much higher quality, making them safer and more effective.https://www.gesundheitsindustrie-bw.de/en/article/news/next-generation-vaccine-production
Press release - 07/10/2020 Joining forces against SARS-CoV-2 Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced an agreement to serve as CDMO partner for BioNTech. As an initial project, Rentschler Biopharma will be responsible for key aspects of cGMP (current good manufacturing practice) drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech.https://www.gesundheitsindustrie-bw.de/en/article/press-release/joining-forces-against-sars-cov-2
Innovative Therapies - 20/08/2020 Labor Dr. Merk is fully committed to viral therapies Labor Dr. Merk & Kollegen is reorienting its business towards viral therapeutics. With this change of strategy, the company, which has decades of expertise in virology, wants to position itself in a timely fashion in the growing new market for advanced therapy medicinal products (ATMP). In gene and virotherapies (oncolytic viruses), tumour vaccines and CAR-T cell therapies, viruses are essential as vectors, killers of tumour cells or…https://www.gesundheitsindustrie-bw.de/en/article/news/labor-dr-merk-fully-committed-viral-therapies
Press release - 11/08/2020 Atriva announces closing of € 8.6 million ($ 10.2 million) oversubscribed convertible loan Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the closing of a € 8.6 million ($ 10.2 million) convertible loan led by Meneldor B.V. and High-Tech Gründerfonds (HTGF), and joined by existing shareholders and new German and international investors.https://www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-announces-closing-eur-86-million-102-million-oversubscribed-convertible-loan
Review article (new edition) - 08/07/2020 Immunology – at the forefront of medical progress Immunology is constantly changing with the emergence of new technologies and areas of application, and has branched out in many directions. Immunological approaches are central to everything – be it the development of innovative active substances and vaccinations against cancer, the search for new therapies against neurodegenerative diseases or autoimmune diseases, or combatting well-known infectious diseases or new virus epidemics.https://www.gesundheitsindustrie-bw.de/en/article/dossier/immunology-forefront-medical-progress
Press release - 17/06/2020 CureVac Receives Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced that the German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have approved the Phase 1 clinical trial for its vaccine program to prevent SARS-CoV-2 infection. The trial will be conducted in Germany and Belgium.https://www.gesundheitsindustrie-bw.de/en/article/press-release/CureVac-Receives-Regulatory-Approval-from-German-and-Belgian-Authorities-to-Initiate-Phase-1-Clinical-Trial-of-its-SARS-CoV-2-Va
Press release - 15/06/2020 German Federal Government invests 300 Million Euros in CureVac The German Federal Minister for Economic Affairs and Energy, Peter Altmaier, and Dietmar Hopp, SAP co-founder and co-founder of the investment company dievini Hopp BioTech holding GmbH & Co. KG, announced today that the Federal Republic of Germany will invest 300 million Euros in the biopharmaceutical company CureVac AG, a pioneer in the preclinical and clinical development of mRNA-based drugs.https://www.gesundheitsindustrie-bw.de/en/article/press-release/german-federal-government-invests-300-million-euros-curevac
Vaccine development - 02/06/2020 CureVac as a pioneer of mRNA technology – what is behind the novel COVID-19 vaccine? All eyes are on vaccines against the coronavirus. The Tübingen-based company CureVac is doing pioneering work in this field, and intends to initiate clinical testing of its lead vaccine candidate in June. At the same time, Curevac is manufacturing the material for this vaccine candidate. But that’s not all: the novel mRNA technology also has the potential to revolutionise the treatment of cancer and metabolic diseases. What makes the method so…https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-als-pionier-der-mrna-technologie-was-steckt-hinter-dem-neuartigen-covid-19-impfstoff
Material research - 25/05/2020 Reaching up into weightlessness – a start-up that enables commercial research experiments in space Yuri, a start-up company founded in 2019 in the Lake Constance area, is aiming high. The company’s mission is to enable microgravity research into the development of materials, new medicines and vaccines, including research opportunities on the International Space Station (ISS). Yuri’s tailor-made solutions are faster and more affordable than previous space research missions.https://www.gesundheitsindustrie-bw.de/en/article/news/reaching-up-into-weightlessness-a-start-up-enables-commercial-research-experiments-in-space
Press release - 14/05/2020 CureVac´s Optimized mRNA Platform Provides Positive Pre-Clinical Results at Low Dose for Coronavirus Vaccine Candidate CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced positive pre-clinical results at a low dose for its lead vaccine candidate against the novel Coronavirus (SARS-CoV-2).https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevacs-coronavirus-impfstoffkandidat-zeigt-dank-optimierter-mrna-plattform-positive-praeklinische-ergebnisse-bei-niedriger-dos
Press release - 13/05/2020 Drug counterfeiters use fear of corona epidemic Falsified chloroquine tablets identified in Africa - University of Tübingen supports local pharmacists in the analysis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/arzneimittelfaelscher-nutzen-angst-vor-corona-epidemie
Prime Vector Technologies GmbH - 09/04/2020 A modular brick system for developing a COVID-19 vaccine Prime Vector Technologies GmbH (PVT), a start-up company based in Tübingen in southern Germany, uses a modular brick system to develop vaccines against cancer and infectious diseases. The PVT team is currently working flat out to develop a COVID-19 vaccine.https://www.gesundheitsindustrie-bw.de/en/article/news/mit-einem-impfstoffbaukasten-gegen-covid-19
Press release - 08/04/2020 New Alliance in the Fight Against Coronavirus and COVID-19 Scientists from Heidelberg and Mannheim launch research and development task forcehttps://www.gesundheitsindustrie-bw.de/en/article/press-release/allianz-im-kampf-gegen-coronavirus-und-covid-19
Press release - 16/03/2020 CureVac focuses on the development of mRNA-based coronavirus vaccine to protect people worldwide CureVac AG, a clinical stage biopharmaceutical company pioneering mRNA-based drugs for vaccines and therapeutics, confirmed today that internal efforts are focused on the development of a coronavirus vaccine with the goal to reach, help and to protect people and patients worldwide.https://www.gesundheitsindustrie-bw.de/en/article/press-release/CureVac-focuses-on-the-development-of-mRNA-based-coronavirus-vaccine-to-protect-people-worldwide